Title |
Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis
|
---|---|
Published in |
Cochrane database of systematic reviews, November 2014
|
DOI | 10.1002/14651858.cd002204.pub3 |
Pubmed ID | |
Authors |
Elphick HE, Southern KW, Elphick, Heather E, Southern, Kevin W |
Abstract |
Allergic bronchopulmonary aspergillosis (ABPA) is an allergic reaction to colonisation of the lungs with the fungus Aspergillus fumigatus and affects around 10% of people with cystic fibrosis. ABPA is associated with an accelerated decline in lung function. High doses of corticosteroids are the main treatment for ABPA; although the long-term benefits are not clear, their many side effects are well-documented. A group of compounds, the azoles, have activity against Aspergillus fumigatus and have been proposed as an alternative treatment for ABPA. Of this group, itraconazole is the most active. A separate antifungal compound, amphotericin B, has been employed in aerosolised form to treat invasive infection with Aspergillus fumigatus, and may have potential for the treatment of ABPA. Antifungal therapy for ABPA in cystic fibrosis needs to be evaluated. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 2 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 20 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 3 | 15% |
Student > Doctoral Student | 3 | 15% |
Student > Master | 3 | 15% |
Researcher | 3 | 15% |
Student > Postgraduate | 2 | 10% |
Other | 4 | 20% |
Unknown | 2 | 10% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 9 | 45% |
Agricultural and Biological Sciences | 2 | 10% |
Biochemistry, Genetics and Molecular Biology | 1 | 5% |
Immunology and Microbiology | 1 | 5% |
Mathematics | 1 | 5% |
Other | 2 | 10% |
Unknown | 4 | 20% |